2025-06-12 –, Posters Display 2
Introduction. Cannabis is one of the most commonly used psychoactive substances globally. It has been shown that motives for cannabis use are related to pattern of use. Cannabidiol (CBD) is a non-intoxicating cannabis compound increasingly used for various purposes, especially among cannabis users. However, there is to date no data on the relationships between cannabis and CBD motives. Understanding such relationships and characterize co-users based on their motives for use can help adapt products characteristics and/or marketing policies to optimize users’ experience.
Methods. We selected cannabis-CBD co-users from the third wave of the European Web Survey on Drugs. We computed Bonferroni-adjusted tetrachoric correlations between cannabis and CBD self-reported motives for use (eight and nine possible motives, respectively). We also computed Spearman’s correlations between number of declared cannabis and CBD motives. Then, we performed an ascending hierarchical classification to identify cannabis-CBD co-user profiles based on their cannabis and CBD motives.
Results. The study sample comprised 15 146 participants (68.1% were men, median age of 26 years). Number of motives for cannabis and CBD use were correlated (Spearman’s ρ=0.49, p<0.001). Similar motives were generally highly correlated between substances. Cluster analysis revealed four different co-user profiles based on cannabis and CBD motives.
Discussion and Conclusions. Users of both cannabis and CBD tend to use them with the same motives. Considering the safe profile of CBD, further research should explore the potential harm-reduction role of CBD products among cannabis users.
Davide Fortin, Univ. Lille, CNRS, IESEG School of Management, UMR 9221 - LEM - Lille Économie Management, F-59000 Lille, France
Vincent Leroy, Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l’Information Médicale, ISSPAM, Marseille, France
Patrizia Carrieri, Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l’Information Médicale, ISSPAM, Marseille, France
Joao Matias, European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Praça Europa 1, Cais do Sodré, 1249-289, Lisbon, Portugal
Tangui Barré, Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l’Information Médicale, ISSPAM, Marseille, France
Davide is a researcher at University of Lille (LEM) where his postdoc focus on the impact of heroin shortages on French users through longitudinal surveys, toxicological analysis and the study of darkweb. He obtained his PhD at Pantheon-Sorbonne University exploring the economics of cannabis regulation and focusing on its integration into the European Health System and the emergence of the market for cannabidiol. Davide is member of the Global Cannabis Cultivation Research Consortium as he’s interested in better understanding domestic cannabis cultivation. Consultant at the United Nations Office for Drugs and Crime on the analysis of drug market sizing and trafficking, Davide is an adjunct lecturer at the University of Padua on medical cannabis economics. He collaborates with MPG Consulting to advise governments in designing cannabis markets.